Immunotherapy for gastrointestinal cancer

Current status and strategies for improving efficacy

Eyad Elkord, Robert E. Hawkins, Peter L. Stern

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Background: Despite improvement in conventional strategies for treating gastrointestinal (GI) carcinoma, large numbers of patients still suffer from incurable or progressive disease. Objective: Here we consider the prospects for circumventing limitations and maximising the efficacy of different immunotherapies. Methods: We summarise different cancer vaccines and targeted drugs and highlight the scientific rationale of using immunotherapy for targeting GI cancers, in addition to the potential strategies for improving immunotherapeutic efficacy. Results/conclusion: Many cancer vaccines and antibody-directed therapies have been tested in early phase clinical trials and demonstrated proof of concept and safety. As yet few have been properly evaluated for clinical efficacy; although adoptive transfer of tumour-associated-antigen-specific T cells has shown dramatic clinical responses in some patients. The recognition of a role for T regulatory cells in limiting anti-tumour immunity has provided momentum for developing strategies to over-ride such immunoinhibitory effects. There is some evidence that conventional therapies may work by influencing these negative factors and allowing expression of immune control mechanisms. An important developing area for clinical evaluation is the testing of combined conventional and immunotherapeutic modalities which may provide for synergy; thereby circumventing the limitations of individualised treatments and generating additional clinical benefits.

Original languageEnglish
Pages (from-to)385-395
Number of pages11
JournalExpert Opinion on Biological Therapy
Volume8
Issue number4
DOIs
Publication statusPublished - Apr 2008
Externally publishedYes

Fingerprint

Cancer Vaccines
Gastrointestinal Neoplasms
Immunotherapy
Tumors
T-cells
Momentum
Adoptive Transfer
Neoplasm Antigens
Regulatory T-Lymphocytes
Antigens
Antibodies
Immunity
Testing
Therapeutics
Clinical Trials
Pharmaceutical Preparations
Carcinoma
T-Lymphocytes
Safety
Neoplasms

Keywords

  • Colorectal cancer
  • Combination therapy
  • Gastrointestinal cancer
  • Immunotherapy
  • T regulatory cells

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Immunotherapy for gastrointestinal cancer : Current status and strategies for improving efficacy. / Elkord, Eyad; Hawkins, Robert E.; Stern, Peter L.

In: Expert Opinion on Biological Therapy, Vol. 8, No. 4, 04.2008, p. 385-395.

Research output: Contribution to journalReview article

@article{361c9c80e11244738d5a89eae8bc05fa,
title = "Immunotherapy for gastrointestinal cancer: Current status and strategies for improving efficacy",
abstract = "Background: Despite improvement in conventional strategies for treating gastrointestinal (GI) carcinoma, large numbers of patients still suffer from incurable or progressive disease. Objective: Here we consider the prospects for circumventing limitations and maximising the efficacy of different immunotherapies. Methods: We summarise different cancer vaccines and targeted drugs and highlight the scientific rationale of using immunotherapy for targeting GI cancers, in addition to the potential strategies for improving immunotherapeutic efficacy. Results/conclusion: Many cancer vaccines and antibody-directed therapies have been tested in early phase clinical trials and demonstrated proof of concept and safety. As yet few have been properly evaluated for clinical efficacy; although adoptive transfer of tumour-associated-antigen-specific T cells has shown dramatic clinical responses in some patients. The recognition of a role for T regulatory cells in limiting anti-tumour immunity has provided momentum for developing strategies to over-ride such immunoinhibitory effects. There is some evidence that conventional therapies may work by influencing these negative factors and allowing expression of immune control mechanisms. An important developing area for clinical evaluation is the testing of combined conventional and immunotherapeutic modalities which may provide for synergy; thereby circumventing the limitations of individualised treatments and generating additional clinical benefits.",
keywords = "Colorectal cancer, Combination therapy, Gastrointestinal cancer, Immunotherapy, T regulatory cells",
author = "Eyad Elkord and Hawkins, {Robert E.} and Stern, {Peter L.}",
year = "2008",
month = "4",
doi = "10.1517/14712598.8.4.385",
language = "English",
volume = "8",
pages = "385--395",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Immunotherapy for gastrointestinal cancer

T2 - Current status and strategies for improving efficacy

AU - Elkord, Eyad

AU - Hawkins, Robert E.

AU - Stern, Peter L.

PY - 2008/4

Y1 - 2008/4

N2 - Background: Despite improvement in conventional strategies for treating gastrointestinal (GI) carcinoma, large numbers of patients still suffer from incurable or progressive disease. Objective: Here we consider the prospects for circumventing limitations and maximising the efficacy of different immunotherapies. Methods: We summarise different cancer vaccines and targeted drugs and highlight the scientific rationale of using immunotherapy for targeting GI cancers, in addition to the potential strategies for improving immunotherapeutic efficacy. Results/conclusion: Many cancer vaccines and antibody-directed therapies have been tested in early phase clinical trials and demonstrated proof of concept and safety. As yet few have been properly evaluated for clinical efficacy; although adoptive transfer of tumour-associated-antigen-specific T cells has shown dramatic clinical responses in some patients. The recognition of a role for T regulatory cells in limiting anti-tumour immunity has provided momentum for developing strategies to over-ride such immunoinhibitory effects. There is some evidence that conventional therapies may work by influencing these negative factors and allowing expression of immune control mechanisms. An important developing area for clinical evaluation is the testing of combined conventional and immunotherapeutic modalities which may provide for synergy; thereby circumventing the limitations of individualised treatments and generating additional clinical benefits.

AB - Background: Despite improvement in conventional strategies for treating gastrointestinal (GI) carcinoma, large numbers of patients still suffer from incurable or progressive disease. Objective: Here we consider the prospects for circumventing limitations and maximising the efficacy of different immunotherapies. Methods: We summarise different cancer vaccines and targeted drugs and highlight the scientific rationale of using immunotherapy for targeting GI cancers, in addition to the potential strategies for improving immunotherapeutic efficacy. Results/conclusion: Many cancer vaccines and antibody-directed therapies have been tested in early phase clinical trials and demonstrated proof of concept and safety. As yet few have been properly evaluated for clinical efficacy; although adoptive transfer of tumour-associated-antigen-specific T cells has shown dramatic clinical responses in some patients. The recognition of a role for T regulatory cells in limiting anti-tumour immunity has provided momentum for developing strategies to over-ride such immunoinhibitory effects. There is some evidence that conventional therapies may work by influencing these negative factors and allowing expression of immune control mechanisms. An important developing area for clinical evaluation is the testing of combined conventional and immunotherapeutic modalities which may provide for synergy; thereby circumventing the limitations of individualised treatments and generating additional clinical benefits.

KW - Colorectal cancer

KW - Combination therapy

KW - Gastrointestinal cancer

KW - Immunotherapy

KW - T regulatory cells

UR - http://www.scopus.com/inward/record.url?scp=42149188994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42149188994&partnerID=8YFLogxK

U2 - 10.1517/14712598.8.4.385

DO - 10.1517/14712598.8.4.385

M3 - Review article

VL - 8

SP - 385

EP - 395

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 4

ER -